Beam Therapeutics Inc. BEAM
25.81 USD +0.66 (+2.62%)
At closeNov 12, 2026, 5:46 AM EST
25.41 -0.40 -1.55%
Pre-market · Nov 12, 5:46 AM ET
24.68 Day range 26.07
20.23 52-week range 38.26
- YTD
- -6.89%
- 1 year
- +14.81%
News
zacks.com BEAM Stock Falls 7% Despite Meeting Primary Endpoints in SCD Study Beam Therapeutics reports positive BEACON study results for risto-cel in sickle cell disease, paving the way for a potential FDA filing by year-end 2026.
benzinga.com Short Interest Powder Kegs: 10 Stocks Bears Cannot Quit Buying Venture Global tops heavily shorted stocks at 90.11% of float, with Sunrun, Ondas, Kohl's and Under Armour also on the list.
benzinga.com Wedbush Maintains Outperform on Beam Therapeutics, Raises Price Target to $33 Wedbush analyst David Nierengarten maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and raises the price target from $30 to $33.
globenewswire.com Beam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell Disease BEACON Trial Achieved Primary Efficacy Endpoint of Freedom from Severe Vaso-occlusive Crises (VOCs) for at Least 12 Consecutive Months, Based on Independently Adjudicated Results, and Met All Primary…
benzinga.com Guggenheim Maintains Buy on Beam Therapeutics, Lowers Price Target to $51 Guggenheim analyst Debjit Chattopadhyay maintains Beam Therapeutics (NASDAQ:BEAM) with a Buy and lowers the price target from $55 to $51.
benzinga.com Canaccord Genuity Maintains Buy on Beam Therapeutics, Lowers Price Target to $78 Canaccord Genuity analyst Whitney Ijem maintains Beam Therapeutics (NASDAQ:BEAM) with a Buy and lowers the price target from $79 to $78.
benzinga.com Wedbush Maintains Outperform on Beam Therapeutics, Raises Price Target to $30 Wedbush analyst David Nierengarten maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and raises the price target from $28 to $30.
benzinga.com Beam Therapeutics To Present Updated Data From Its BEACON Phase 1/2 Study Of Ristoglogene Autogetemcel In Sickle Cell Disease At 68th American Society of Hematology Annual Meeting Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated data from the BEACON…
benzinga.com Beam Therapeutics Q3 EPS $(1.28) Misses $(1.15) Estimate, Sales $307.000K Miss $8.752M Estimate Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.28) per share which missed the analyst consensus estimate of $(1.15) by 11.3 percent. This is a 16.36 percent decrease over losses of…
benzinga.com Bears Load Up on Ondas, Dutch Bros and 8 More Stocks — Is a Squeeze Brewing? Ondas, Dutch Bros and Under Armour are among the most-heavily shorted stocks in the market right now.- benzinga.com Canaccord Genuity Maintains Buy on Beam Therapeutics, Raises Price Target to $79 Canaccord Genuity analyst Whitney Ijem maintains Beam Therapeutics (NASDAQ:BEAM) with a Buy and raises the price target from $78 to $79.
- benzinga.com Wedbush Maintains Outperform on Beam Therapeutics, Lowers Price Target to $28 Wedbush analyst David Nierengarten maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and lowers the price target from $65 to $28.
- benzinga.com Beam Therapeutics Announces Initial Data From Its Ongoing Phase 1/2 Clinical Trial Evaluating BEAM-301 For Treatment Of Glycogen Storage Disease Type Ia; In The 40 Mg Cohort, Two Patients Achieved 15 Hours Of Controlled Fasting; Safety Profile Of BEAM-301 Consistent With LNP-Based Therapies The data will be presented during a poster session at the 33rd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) in Hamburg, Germany. BEAM-301 is an investigational…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $80 price target.
- benzinga.com Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target Wedbush analyst David Nierengarten reiterates Beam Therapeutics (NASDAQ:BEAM) with a Outperform and maintains $65 price target.
benzinga.com Top 10 Powder Keg Stocks Where Short Sellers Are Sitting on a Fuse Dutch Bros, SoundHoundAI, Kohl's and Ondas are among the top ten most-heavily shorted stocks in the market right now.- benzinga.com Beam Therapeutics To Present Initial Data From Ongoing Phase 1/2 Clinical Trial Evaluating BEAM-301 For Treatment Of Glycogen Storage Disease Type Ia At 33rd Annual Congress Of ESGCT BEAM-301 Achieves Clinical Proof of Concept for Genetic Correction of R83C Mutation in GSDIaInitial Phase 1/2 Data Show Restoration of Endogenous Glucose Production Following a Single Treatment, with…